Aelis Farma
Develops CB1-targeted drug candidates for people with cannabis-related disorders and cognitive deficits
Highlights
- New on EvolcAdded 2026-10-30
About Aelis Farma
Aelis Farma is a biopharmaceutical company developing signaling-specific inhibitors of the CB1 receptor, a pharmacological class intended to address brain disorders while preserving normal receptor activity. Its pipeline includes AEF0117 for cannabis-related disorders and AEF0217 for cognitive deficits, initially targeting Down syndrome.
The company develops therapeutic candidates for people with brain disorders with unmet medical needs. Its headquarters is in Pessac, France, and it lists a laboratory facility in Pessac and a headquarters address in Bordeaux.
Product: Develops CB1 signaling-specific inhibitor drug candidates, including AEF0117 and AEF0217.
Jobs at Aelis Farma
More biotech & pharma companies
Aenitis Technologies
Acoustic levitation cell-handling devices and single-use consumables for cell and gene therapy bioprocessingNew on EvolcAffilogic
Develops Nanofitin-based therapeutics and custom binding proteins for pharmaceutical and biotech partnersNew on EvolcAffinisep
Sample preparation kits and SPE cartridges for analytical labs in proteomics, metabolomics, and water analysisNew on EvolcAfyia Diagnostics
PCR diagnostic kits for infectious disease testing by clinical and research laboratoriesYoung companyNew on EvolcAlliance Bio Expertise
Automated microbiology lab equipment and culture media for food, cosmetics, pharma and clinical labsNew on EvolcAnalysis Expertise
Forensic toxicology and genetic testing for courts and law enforcement agenciesYoung companyNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- Nuxt
- Tailwind CSS
- Vue